Navigation Links
Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting

ormation, please visit our website (www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward- looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 15, 2007 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

     Contact:

     Denise T. Powell

     Sr. Director, Corporate Communications

     Threshold Pharmaceuticals, Inc.

     650-474-8206
dpowell@thresholdpharm.com

CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, dpowell@thresholdpharm.com

Web site:




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/2/2008)...e/ -- Researchers using functional,MRI (fMRI) hav... brain,responsible for suppressing memory is dysf...ed psychiatric disorders. Results of the study wil... Radiological Society of North America,(RSNA). ,...er stress-related disorders,traumatic memories a...
(Date:12/2/2008)...IBT Laboratories, a leading clinical-diagnostics ... immunology and allergy assays, announced that it ...of patients whose immune systems may be compromise...otherapy drugs, or because they are taking immuno-...lant. The company launched the two new assays, the...
(Date:12/2/2008)...stCall/ -- Micromet, Inc. (Nasdaq: MITI ), a bio...ry antibodies for the treatment of cancer, inflamm...t it has entered into an agreement expanding its C...gsbridge Capital Limited, a private investment gro... has committed to provide up to $75 million of cap...
(Date:12/1/2008)...rstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ... the world,s leading medical journals, results of ...experimental compound tasimelteon (VEC-162). The ...latonin agonist tasimelteon (VEC-162) for transien...controlled multicentre trials." Results are report...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Stomach ulcer bug causes bad breath 5990 1Stomach ulcer bug causes bad breath 5990 2Ultrasound waves aid in rapid treatment of DVT 30399 1Ultrasound waves aid in rapid treatment of DVT 30399 2Scripps research team defines new painkilling chemical pathway 5988 1Scripps research team defines new painkilling chemical pathway 5988 2AirMed International wins Air Ambulance of the Year for Second Consecutive Year 30392 1AirMed International wins Air Ambulance of the Year for Second Consecutive Year 30392 2
(Date:12/3/2008)...e/ -- MedQuist Inc. (Nasdaq: MEDQ ), the largest... in the world, is pleased to announce the positive... , Resolution of the DOJ Investigation , ...d an administrative HIPAA subpoena for documents f...) on December 17, 2004. The subpoena sought inform...
(Date:12/3/2008)...c study found that patients with low-grade gliomas...urgeries to successfully remove the entire tumor. ...le, patients survived significantly longer when su...y is available online as an advance publication in...nals.org/cgi/content/abstract/15228517-2008-102v1 ...
(Date:12/3/2008)...e/ -- The American College of Surgeons (ACS) today...s committee report on resident duty hours that was...e on Optimizing Graduate Medical Trainee (Resident...ty. , , ACS agrees with the IOM in its co...0-hour work week (averaged over four weeks) are no...
(Date:12/3/2008)...ora Health Care,s Women,s Pavilion,( http://www.a...Salon and Spa of,New Berlin partnered for a new k...ink hair extensions. , Throughout the month...for,$15 each at the Aurora Women,s Pavilion in We... Spa in New Berlin. The profits from these bright ...
Breaking Medicine News(10 mins):Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2
...vidence that sage can significantly improve memory...might be the key to treating Alzheimer's disease. ...volunteers between ages 18 and 37. Some were given...n placebos. In a word recall test, those who took ...
...s is better at reducing problems in heart transpla...Specifically the drug reduced the incidence of a s...e graft known as coronary vasculopathy.// Previous...ed with another drug reduced the rejection and ris...
...re more vulnerable to serious brain injuries when ...abuse investigators distinguish between accidental...ylvania study found that rotational forces generat...face can cause widespread, potentially serious bra...
... increasingly common procedure for hard-to-treat c...But it can take months or even years for stem cell...he patient is at risk for serious infection. Now, ...one step further with incredible results. Ed Baute...
Other Medicine News:
...ex® Thermovent® T helps provide protection.... It is small and extremely lightweight making it ... With a high rate of heat and moisture recovery, i...tention., ,All HMEs and filters have ISO standard...
...ex® Thermovent® T helps provide protection.... It is small and extremely lightweight making it ... With a high rate of heat and moisture recovery, i...tention., ,All HMEs and filters have ISO standard...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines
Medicine Products: